The global dermatomyositis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Dermatomyositis is a rare disease that is used to describe muscle and skin symptoms. It causes muscle inflammation and skin rash. Additionally, it causes muscle inflammation and swelling and is different from other muscle diseases as it also causes skin problems. The major factor driving the demand for dermatomyositis drug is the increasing prevalence of dermatomyositis disease across the globe.
According to the National Organization for Rare Diseases, dermatomyositis most commonly occurs between ages 40 to 60, however, it can occur in people of all ages or at any time from infancy through approximately age 80. Additionally, its prevalence is estimated at 9.63 cases per million people. Furthermore, its symptoms usually appear between the ages of 5 to 15 years in children. Moreover, an estimated 3 in 1,000,000 children are affected by juvenile dermatomyositis. Apart from this, females are affected twice as often as males by this disease. Hence, the increasing prevalence of dermatomyositis is driving the demand for dermatomyositis drugs for treatment which in turn is driving the growth of the market.
To Request a Sample of our Report on Dermatomyositis Drug Market: https://www.omrglobal.com/request-sample/dermatomyositis-drug-market
Some major players in the market include Pfizer Inc., Eli Lilly and Company, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2021, Octapharma Group announced the approval of Octagam 10% from the US FDA. Octagam 10% is an immune globulin intravenous liquid preparation indicated for the treatment of dermatomyositis in adults.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Pfizer Inc., Eli Lilly and Company, and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A full Report of Dermatomyositis Drug Market is Available @ https://www.omrglobal.com/industry-reports/dermatomyositis-drug-market
Global Dermatomyositis Drug Market Report by Segment
By Type
- Abatacept
- Baricitinib
- Dalazatide
- Immune Globulin
- IMO-8400
By Application
- Hospital
- Clinic
- Others
Global Dermatomyositis Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
